ASML: Q3 Results Better - But Not Good Enough (NASDAQ:ASML)
ASML reported stronger than expected Q3 results, generating €5.8 billion of revenues and EPS of €4.29. See why investing in ASML stock is not yet attractive.
Stay updated with breaking news from Michael Vi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ASML reported stronger than expected Q3 results, generating €5.8 billion of revenues and EPS of €4.29. See why investing in ASML stock is not yet attractive.
Keysight shares have held in relatively well this year and offer an attractive GARP opportunity at 19x earnings. See why I recommend building positions in KEYS.
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases
Palantir Technologies' fiscal 2022 topline guidance was below expectations. Click here to read why I lower my rating for PLTR stock from a buy to a hold.
Okta's acquisition of AuthO came with hidden pitfalls, and it was recently forced to reduce its forecast for the next 2 quarters for revenues. Read more here.